Digestive and Liver Disease
Volume 42, Issue 4 , Pages 253-260 , April 2010

Cholangiocarcinoma: Update and future perspectives

  • Manuela Gatto

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Maria Consiglia Bragazzi

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Rossella Semeraro

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Cristina Napoli

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Raffaele Gentile

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Alessia Torrice

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Eugenio Gaudio

      Affiliations

    • Department of Anatomy, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Domenico Alvaro

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • Corresponding Author InformationCorresponding author at: Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Polo Pontino, R. Rossellini 51, 00137 Rome, Italy. Tel.: +39 06 49972023; fax: +39 06 4453319.

Received 18 November 2009 ,Accepted 28 December 2009.

References 

  1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321
  2. Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875
  3. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008;14:6458–6466
  4. Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69:259–270
  5. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303–1314
  6. Il Colangiocarcinoma. commissione aisf 2009; www.webaisf.com.
  7. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215:31–38
  8. Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut. 2007;56:1755–1756
  9. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131–150
  10. Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:6289–6297
  11. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol. 2008;42:178–190
  12. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol. 2009;15:4240–4262
  13. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:77–82
  14. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol. 2004;40:472–477
  15. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int. 2006;26:1047–1053
  16. Blendis L, Halpern Z. An increasing incidence of cholangiocarcinoma: why?. Gastroenterology. 2004;127:1008–1009
  17. Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594–603
  18. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  19. Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarcinoma. Ann Surg. 2009;249:541–542
  20. Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99:895–897
  21. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28:921–925
  22. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751–1758
  23. Borie F, Trétarre B, Bouvier AM, et al. Primitive liver cancers: epidemiology and geographical study in France. Eur J Gastroenterol Hepatol. 2009;21:984–989
  24. Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer. 2009;40:19–25
  25. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205–1211
  26. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526
  27. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006;26:42–51
  28. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48:1106–1117
  29. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case–control study in Pusan, Korea. Int J Epidemiol. 1996;25:933–940
  30. Kim HG, Han J, Kim MH, et al. Prevalence of clonorchiasis in patients with gastrointestinal disease: a Korean nationwide multicenter survey. World J Gastroenterol. 2009;15:86–94
  31. Poomphakwaen K, Promthet S, Kamsa-Ard S, et al. Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case–control study. Asian Pac J Cancer Prev. 2009;10:251–258
  32. Andoh H, Yasui O, Kurokawa T, et al. Cholangiocarcinoma coincident with schistosomiasis japonica. J Gastroenterol. 2004;39:64–68
  33. National Toxicology Program. NTP toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS No. 57117-31-4), and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague–Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser. 2006;1–180
  34. Sahani D, Prasad SR, Tannabe KK, et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging. 2003;28:72–74
  35. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002;195:713–718
  36. de Vries JS, de Vries S, Aronson DC, et al. Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg. 2002;37:1568–1573
  37. Pisano G, Donlon JB, Platell C, et al. Cholangiocarcinoma in a type III choledochal cyst. Aust N Z J Surg. 1991;61:855–857
  38. Voyles CR, Smadja C, Shands WC, et al. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983;118:986–988
  39. Su CH, Shyr YM, Lui WY, et al. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84:969–973
  40. Ishiguro S, Inoue M, Kurahashi N, et al. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control. 2008;19:33–41
  41. Tashiro S, Imaizumi T, Ohkawa H, et al. Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg. 2003;10:345–351
  42. Miyazaki M, Takada T, Miyakawa S, et al. Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors. J Hepatobiliary Pancreat Surg. 2008;15:15–24
  43. Gwak GY, Yoon JH, Lee SH, et al. Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. J Cancer Res Clin Oncol. 2006;132:771–779
  44. Costamagna G, Tringali A, Shah SK, et al. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. Endoscopy. 2002;34:273–279
  45. Strömberg C, Luo J, Enochsson L, et al. Endoscopic sphincterotomy and risk of malignancy in the bile ducts, liver, and pancreas. Clin Gastroenterol Hepatol. 2008;6:1049–1053
  46. Mortensen FV, Jepsen P, Tarone RE, et al. Endoscopic sphincterotomy and long-term risk of cholangiocarcinoma: a population-based follow-up study. J Natl Cancer Inst. 2008;100:745–750
  47. Chuang SC, Vecchia CL, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2008;286:9–14
  48. Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case–control study in Italy. Cancer Causes Control. 2001;12:959–964
  49. Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer. 2009;100:1765–1770
  50. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471–2477
  51. Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case–control study in China. World J Gastroenterol. 2008;14:632–635
  52. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009;49:116–123
  53. Wu TT, Levy M, Correa AM, et al. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer. 2009;115:4564–4575
  54. Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case–control study. Eur J Gastroenterol Hepatol. 2007;19:623–630
  55. Cardinale V, Wang Y, Carpino G, et al. Multipotent stem/progenitor cells in human extrahepatic biliary tree yield hepatocytes, bile ducts and pancreatic islets. Am Assoc Study Liver Dis. 2009;
  56. Nomoto K, Tsuneyama K, Cheng C, et al. Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. Pathol Res Pract. 2006;202:71–76
  57. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989;134:1347–1363
  58. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–1556
  59. Sasaki M, Yamaguchi J, Ikeda H, et al. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma tissue and culture studies. Hum Pathol. 2009;40:1723–1730
  60. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667
  61. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184–190
  62. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–G634
  63. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83
  64. Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008;14:2986–2989
  65. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5–15
  66. Prawan A, Buranrat B, Kukongviriyapan U, et al. Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2009;135:515–522
  67. Pinlaor S, Sripa B, Ma N, et al. Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World J Gastroenterol. 2005;11:4644–4649
  68. Mon NN, Kokuryo T, Hamaguchi M. Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma. Methods Mol Biol. 2009;512:279–293
  69. Boberg KM, Schrumpf E, Bergquist A, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol. 2000;32:374–380
  70. Furubo S, Harada K, Shimonishi T, et al. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 1999;35:230–240
  71. Watanabe M, Asaka M, Tanaka J, et al. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology. 1994;107:1147–1153
  72. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer. 1992;69:1115–1118
  73. Ahrendt SA, Rashid A, Chow JT, et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg. 2000;7:426–431
  74. Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2002;49:604–608
  75. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 1991;51:3497–3502
  76. Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000;47:721–727
  77. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest. 1999;79:477–483
  78. Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 1998;58:1124–1126
  79. Taniai M, Higuchi H, Burgart LJ, et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002;123:1090–1098
  80. Goydos JS, Brumfield AM, Frezza E, et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg. 1998;227:398–404
  81. Yokomuro S, Tsuji H, Lunz JG, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology. 2000;32:26–35
  82. Park J, Tadlock L, Gores GJ, et al. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30:1128–1133
  83. Tadlock L, Patel T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology. 2001;33:43–51
  84. Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005;42:1329–1338
  85. Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054–2065
  86. Itatsu K, Sasaki M, Yamaguchi J, et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol. 2009;174:829–841
  87. Han C, Leng J, Demetris AJ, et al. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004;64:1369–1376
  88. Nzeako UC, Guicciardi ME, Yoon JH, et al. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35:552–559
  89. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol. 2004;287:G88–G95
  90. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–993
  91. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053–24063
  92. Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:7033–7058
  93. Lai GH, Zhang Z, Shen XN, et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005;129:2047–2057
  94. Aishima SI, Taguchi KI, Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40:269–278
  95. Yoon JH, Gwak GY, Lee HS, et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004;41:808–814
  96. Choi HJ, Kim HJ, Choi JH. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2009;56:606–609
  97. Socoteanu MP, Mott F, Alpini G, et al. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 2008;14:2990–2994
  98. Komori J, Marusawa H, Machimoto T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology. 2008;47:888–896
  99. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology. 2007;132:415–431
  100. Marzioni M, Fava G, Benedetti A. Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol. 2006;12:3471–3480
  101. Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 2005;65:11437–11446
  102. Coufal M, Invernizzi P, Gaudio E, et al. Increased local dopamine secretion has growth promoting effects in cholangiocarcinoma. Int J Cancer. 2009;
  103. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–888
  104. Mancino A, Mancino MG, Glaser SS, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2009;41:156–163
  105. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs. World J Gastroenterol. 2007;13:6465–6469
  106. Sandhu DS, Shire AM, Roberts LR. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int. 2008;28:12–27
  107. Isomoto H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio-carcinoma due to SOCS3 epigenetic silencing. Digestion. 2009;79:2–8
  108. Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008;27:378–386
  109. Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26:6133–6140
  110. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004;24:139–154
  111. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108:865–869
  112. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med. 2007;147:451–459
  113. Björnsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999;19:501–508
  114. Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 2009;45:33–47
  115. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317–323
  116. Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg. 2008;25:126–132
  117. Schulick RD. Primary sclerosing cholangitis: detection of cancer in strictures. J Gastrointest Surg. 2008;12:420–422
  118. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–284
  119. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56:40–47
  120. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734–1740
  121. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:204–207
  122. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–518
  123. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54–61
  124. Akdoğan M, Saşmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87:337–339
  125. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci. 1988;33:1223–1225
  126. Lempinen M, Isoniemi H, Mäkisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol. 2007;47:677–683
  127. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007;247:301–308
  128. Boonla C, Sripa B, Thuwajit P, et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11:4939–4946
  129. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:583–589
  130. Klump B, Hsieh CJ, Dette S, et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res. 2003;9:1773–1778
  131. Su WC, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors βFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci. 2001;46:1387–1392
  132. Manfredi R, Barbaro B, Masselli G, et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155–164
  133. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis. 2004;24:165–175
  134. Watanabe H, Enjoji M, Nakashima M, et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J Hepatol. 2003;39:559–563
  135. Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–411
  136. Ebata T, Watanabe H, Ajioka Y, et al. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89:1260–1267
  137. Yamaguchi K, Chijiiwa K, Saiki S, et al. Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology. 1997;44:1256–1261
  138. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:14–22
  139. Greene FL, Page DL, Fleming ID. AJCC (American Joint Committee on Cancer) cancer staging manual. 6th ed.. New York: Springer-Verlag; 2002;
  140. Kondo S, Takada T, Miyazaki M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15:41–54
  141. Rocha FG, Matsuo K, Blumgart LH, et al. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Surg. 2009;
  142. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Surg. 2009;
  143. Young AL, Prasad KR, Toogood GJ, et al. Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centers, Leeds. J Hepatobiliary Pancreat Surg. 2009;
  144. Witzigmann H, Lang H, Lauer H. Guidelines for palliative surgery of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:154–160
  145. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–372
  146. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675–680
  147. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686–691
  148. Singal A, Welling TH, Marrero JA. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther. 2009;9:491–502
  149. Schwartz JJ, Hutson WR, Gayowski TJ, et al. Liver transplantation for cholangiocarcinoma. Transplantation. 2009;88:295–298
  150. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–207
  151. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–458
  152. Zoepf T. Photodynamic therapy of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:161–163
  153. Baisden JM, Kahaleh M, Weiss GR, et al. Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma. Gastrointest Cancer Res. 2008;2:219–224
  154. Kiesslich T, Wolkersdörfer G, Neureiter D, et al. Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci. 2009;8:23–30
  155. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–969
  156. Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol. 2005;19:711–716
  157. Lee MA, Woo IS, Kang JH, et al. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2004;130:346–350
  158. Yamashita Y, Taketomi A, Fukuzawa K, et al. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Res. 2006;26:771–775
  159. Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007;72:105–110
  160. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37:843–851
  161. Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008;53:564–570
  162. Charoentum C, Thongprasert S, Chewaskulyong B, et al. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol. 2007;13:2852–2854
  163. Lee J, Kim TY, Lee MA, et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2008;61:47–52
  164. Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007;60:295–303
  165. Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98:309–315
  166. Blechacz BR, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009;
  167. Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009;35:322–327
  168. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–1695
  169. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178–182

☆ D. Alvaro was supported by MIUR grants: PRIN #2007, prot. 2007HPT7BA_003. E. Gaudio was supported by MIUR grants: PRIN#2007, prot. 2007HPT7BA_001 and Federate Atheneaum funds from University “Sapienza” of Rome.

PII: S1590-8658(10)00003-4

doi: 10.1016/j.dld.2009.12.008

Digestive and Liver Disease
Volume 42, Issue 4 , Pages 253-260 , April 2010

Article Tools